Using imlifidase to elucidate the characteristics and importance of anti-GBM antibodies produced after start of treatment.

Tyrberg, Linnéa; Andersson, Fanny; Uhlin, Fredrik; Hellmark, Thomas; Segelmark, Mårten

Tyrberg, Linnéa; Andersson, Fanny; Uhlin, Fredrik; Hellmark, Thomas; Segelmark, Mårten.

Afiliação

Tyrberg L; Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Andersson F; AT-unit, Helsingborg Hospital, Helsingborg, Sweden.
Uhlin F; Department of Clinical Sciences Lund, Lund University, Lund, Sweden.
Hellmark T; Department of Nephrology and Department of Health, Medicine and Caring Sciences, Linköping University, Linköping, Sweden.
Segelmark M; Department of Health Technologies, Tallinn University of Technology, Tallinn, Estonia.

Nephrol Dial Transplant ; 39(1): 45-54, 2023 Dec 20.

Article em En | MEDLINE | ID: mdl-37385828

Assuntos

Doença Antimembrana Basal Glomerular; Anticorpos Anticitoplasma de Neutrófilos; Humanos; Diálise Renal; Autoanticorpos; Doença Antimembrana Basal Glomerular/tratamento farmacológico; Imunossupressores/uso terapêutico; Epitopos/uso terapêutico; Imunoglobulina G

Palavras-chave

anti-GBM disease; autoantibody-mediated renal disease; double positivity; epitope specificity; subclass distribution

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Anticorpos Anticitoplasma de Neutrófilos / Doença Antimembrana Basal Glomerular Idioma: En Ano de publicação: 2023 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google